News

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...
Stocktwits on MSN5d
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data
Shares of Quoin Pharmaceuticals saw increased retail chatter on Wednesday after the company announced positive initial ...
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster ...
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday
Shares of Quoin Pharmaceuticals surged 47.5% Wednesday morning. The stock is higher following the release of promising ...
The Manila Times6d
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial ...
Investing.com6d
Quoin berichtet über Fortschritte bei Studie zu Hauterkrankungen bei Kindern
Der Patient hat gut auf QRX003 angesprochen, ohne dass unerwünschte Ereignisse gemeldet wurden, und die Behandlung soll mit einer weiteren Bewertung nach 24 Wochen fortgesetzt werden. Die positiven ...
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
The Manila Times7d
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...
Healthline14d
Einstein Syndrome: Characteristics, Diagnosis, and Treatment
Most people assume that a language delay or speech disorder will have a long-term impact on a child’s ability to excel in school and beyond. But a lesser known condition called Einstein syndrome ...
American Association of Individual Investors14d
Why Krystal Biotech, Inc.’s (KRYS) Stock Is Down 12.19%
Krystal Biotech, Inc.’s KRYS share price has dipped by 12.19%, which has investors questioning if this is right time to buy.
Investing14d
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid HAE market growth
Key developments include: 1. BCX17225 for Netherton Syndrome: The company is progressing with clinical trials for this rare genetic skin disorder, with data expected later in the year. 2. Avoralstat ...